Erydel
Red-blood-cell-based drug delivery device for the treatment of rare neurodegenerative diseases.
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 12 % | (99 %) | (97 %) | - | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (1547 %) | (3602 %) | (465392 %) | (17186736 %) | - | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1584 %) | (3665 %) | (498516 %) | (17926926 %) | - | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Dealroom estimates
Related Content
EryDel is a biotechnology company focused on developing and commercializing specialized therapies for the treatment of rare diseases. The company utilizes a proprietary platform technology that encapsulates therapeutic enzymes and other molecules within red blood cells. This innovative approach allows for prolonged half-life in circulation, reduced immunogenicity, better tolerability, and predictable vascular distribution. EryDel primarily serves patients suffering from rare diseases, offering them advanced therapeutic options that are not widely available in the market. The company operates in the biopharmaceutical sector, targeting niche markets with high unmet medical needs. EryDel's business model revolves around research and development, clinical trials, and eventual commercialization of its therapies. Revenue is generated through the sale of these specialized treatments, as well as potential partnerships and licensing agreements with other pharmaceutical companies.
Keywords: biotechnology, rare diseases, red blood cell encapsulation, therapeutic enzymes, prolonged half-life, reduced immunogenicity, better tolerability, vascular distribution, biopharmaceutical, niche markets.